Montrouge, France, February 20 2024
DBV Technologies to Participate in
Upcoming AAAAI 2024 Congress
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical
company focused on treatments for food allergies, today announced
two presentations at the American Academy of Allergy, Asthma, and
Immunology (AAAAI) Annual Meeting, February 23-26 in Washington,
D.C.
A poster presentation by David Fleischer, M.D.
of Children’s Hospital Colorado will describe the long-term
(five-year) safety results of epicutaneous immunotherapy (EPIT)
with Viaskin™ Peanut in peanut-allergic children aged 4-11 years in
the PEOPLE (PEPITES Open-Label Extension) Phase 3 study.
An oral presentation, in collaboration with
Icahn School of Medicine at Mount Sinai and Beckman Coulter Life
Sciences, will describe how the immune modifying effects of Viaskin
Peanut treatment over time were characterized in toddlers using a
streamlined, novel approach to basophil activation testing (BAT)
during the multicenter Phase 3 EPITOPE trial of in children aged
1-3 years.
DBV is sponsoring a non-CME Product Theater
titled “Importance of Early Intervention for Peanut Allergy.”
Professors Hugh Sampson, M.D. and Julie Wang, M.D., of the Icahn
School of Medicine at Mount Sinai, and David Fleischer, M.D., of
Children’s Hospital Colorado, will discuss the clinical benefits of
early treatment initiation for peanut allergy through case-based
learning. The panelists will also address how they navigate the
shared decision-making process with families soon after a peanut
allergy diagnosis, including factors related to clinical trial
participation, such as eligibility and understanding barriers to
enrollment. The Product Theater is scheduled for Saturday, February
24, from 10:00 a.m. to 10:30 a.m. EST in the Walter E.
Washington Convention Center, Level 2, Hall D.
DBV is proud to sponsor the AAAAI
Fellows-in-Training (FIT) Program reception on Friday, February 23.
The private reception welcomes current allergy/immunology
Fellows-in-Training.
DBV will host a booth (#567) in the AAAAI
exhibit hall where attendees can learn more about epicutaneous
immunotherapy with Viaskin, including our ongoing clinical trials
in peanut-allergic children.
“The five-year safety data from our PEOPLE
open-label extension study of Viaskin Peanut in children aged 4-11
years demonstrate that the long-term safety profile of Viaskin
Peanut 250 μg is consistent with safety results observed in shorter
(one-year, three-years) treatment periods,” said Pharis Mohideen,
M.D. Chief Medical Officer at DBV Technologies.
“At DBV, we look forward to a day when
allergists and families of children with peanut allergy have
multiple approved treatment options and together decide on the best
therapy for each child’s situation,” continued Dr. Mohideen. “DBV,
is committed to generating robust, long-term safety data with
Viaskin Peanut to aid in future shared decision-making. To that
end, our ongoing clinical programs evaluating Viaskin Peanut in
children ages 4-7 and toddlers ages 1-3 will each comprise
approximately 600 patients in the active treatment arms.”
“As part of a collaboration with Icahn School of
Medicine at Mount Sinai and Beckman Coulter Life Sciences, basophil
activation testing, a blood test also known as BAT, was conducted
on over 100 Viaskin Peanut participants aged 1-3 years, who were
enrolled in DBV’s Phase 3 EPITOPE trial,” continued Dr. Mohideen.
“This novel form of BAT, streamlined by Beckman Coulter to be more
easily implemented at clinical sites, was used to help understand
the immune modifying effects of epicutaneous immunotherapy over
time. This could help advance our understanding of BAT as a
potential treatment monitoring tool.”
DBV Abstract Details:
Oral Abstract Presentation
“A Streamlined Approach to Basophil
Activation Testing for Longitudinal Characterization of Toddlers
with Peanut Allergy During a Multi-Site Phase 3 Double-Blind
Placebo-Controlled Trial of Epicutaneous Immunotherapy
(EPIT)” will be presented by Dr. Jean-Marc Busnel (Beckman
Coulter)
- Presentation date: Saturday,
February 24, 2024
- Presentation time: 2:15 p.m. – 2:25
p.m. ET
- Presentation location: Convention
Center, Level 3, Ballroom B
Poster Presentation
“Long-term Safety Results of
Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in
Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE
Study” will be presented by Dr. David Fleischer, Associate
Professor of Pediatrics at Children’s Hospital Colorado.
- Poster number: 379
- Session title: Treatment and
Management of IgE-mediated Food Allergy
- Presentation date: Saturday,
February 24, 2024
- Presentation time: 9:45 a.m. –
10:45 a.m. ET
- Presentation location: Convention
Center, Level 2, Hall D
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including, but not limited to, statements regarding the therapeutic
potential of Viaskin™ Peanut and EPIT™ and DBV’s planned regulatory
and clinical efforts including timing and results of communications
with regulatory agencies, and the ability of any of DBV’s product
candidates, if approved, to improve the lives of patients with food
allergies. These forward-looking statements and estimates are not
promises or guarantees and involve substantial risks and
uncertainties. At this stage, DBV’s product candidates have not
been authorized for sale in any country. Among the factors that
could cause actual results to differ materially from those
described or project herein include uncertainties associated
generally with research and development, clinical trials and
related regulatory reviews and approvals. A further list and
description of risks and uncertainties that could cause actual
results to differ materially from those set forth herein can be
found in DBV Technologies’ regulatory filings with the Autorité des
Marchés Financiers (“AMF”), DBV Technologies’ filings and reports
with the U.S. Securities and Exchange Commission (“SEC”), and
future filings and reports made with the AMF and SEC. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements and estimates, which speak only as
of the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAurora KrauseDBV
Technologiesaurora.krause-ext@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Nov 2024 to Dec 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Dec 2023 to Dec 2024
